Evidence map›Paper›PMID 33208502›Full record

ArticleScience translational medicine2020

Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis.

Hendy Kristyanto, Nienke J Blomberg, Linda M Slot, Ellen I H van der Voort, Priscilla F Kerkman, Aleida Bakker, Leonie E Burgers, Robin M Ten Brinck, Annette H M van der Helm-van Mil, Hergen Spits and 4 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05502731 (Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis), which is not on this map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05502731 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

TypeinterventionalSponsorLeiden University Medical CenterRan2022 to 2025Enrolled40ConditionsRheumatoid ArthritisArmsFilgotinib, Adalimumab
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Cross-presentation of citrullinated antigens drives cytotoxic CD8bioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Depleting Autoreactive B‑Cells Using Targeted Photodynamic Therapy.ACS pharmacology & translational science · 2025
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Hendy KristyantoDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.ORCID 0000-0002-8022-6637
Nienke J BlombergDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.
Linda M SlotDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.
Ellen I H van der VoortDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.
Priscilla F KerkmanDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.ORCID 0000-0002-6212-002X
Aleida BakkerDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.
Leonie E BurgersDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.
Robin M Ten BrinckDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.ORCID 0000-0002-6128-6888
Annette H M van der Helm-van MilDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.
Hergen SpitsDepartment of Experimental Immunology and Amsterdam Institute of Infection and Immunity, Amsterdam University Medical Center, location AMC, 1105AZ Amsterdam, Netherlands.ORCID 0000-0003-3269-8338
Dominique L BaetenDepartment of Clinical Immunology and Rheumatology, Amsterdam University Medical Center, location AMC, 1105AZ Amsterdam, Netherlands.
Tom W J HuizingaDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.ORCID 0000-0001-7033-7520
René E M ToesDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands.ORCID 0000-0002-9618-6414
Hans U SchererDepartment of Rheumatology, Leiden University Medical Center, 2300RC Leiden, Netherlands. h.u.scherer@lumc.nl.ORCID 0000-0002-5700-5617
Leiden University Medical Center · NLAIMM Therapeutics (Netherlands) · NLAmsterdam University Medical Centers · NL

Funding

European Research Council 714312
6 · The paper itself

Abstract

Autoreactive B cells mediate autoimmune pathology, but exactly how remains unknown. A hallmark of rheumatoid arthritis (RA), a common autoimmune disease, is the presence of disease-specific anticitrullinated protein antibodies (ACPAs). Here, we showed that ACPA-positive B cells in patients with RA strongly expressed T cell-stimulating ligands, produced abundant proinflammatory cytokines, and were proliferative while escaping inhibitory signals. This activated state was found at different degrees in different stages of disease: highest in patients with recent-onset RA, moderate in patients with established RA, and far less pronounced in ACPA-positive individuals "at risk" for developing disease. The activated autoreactive B cell response persisted in patients who achieved clinical remission with conventional treatment. ACPA-positive B cells in blood and synovial fluid secreted increased amounts of the chemoattractant interleukin-8, which attracted neutrophils, the most abundant immune cell in arthritic joints. Tetanus toxoid-specific B cells from the same patients exhibited properties of memory B cells without the activation and proliferation phenotype, but these cells transiently acquired a similar proliferative phenotype upon booster vaccination. Together, these data indicated that continuous antigenic triggering of autoreactive B cells occurs in human autoimmune disease and support the emerging concept of immunological activity that persists under treatment even in clinical remission, which may revise our current concept of treatment targets for future therapeutic interventions. In addition, our data pointed to a pathogenic role of ACPA-positive B cells in the inflammatory disease process underlying RA and favor approaches that aim at their antigen-specific inactivation or depletion.

Indexed as

Arthritis, RheumatoidAutoantibodiesB-LymphocytesHumansInflammationSynovial FluidAutoantibodies

Identifiers

PMID33208502
PMCPMC7615909
OpenAlexW3106098975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.